Fig. 4

MJ04 induces early onset in anagen development, hair cycle progression in nude mice, and growth of human hair follicles under ex-vivo conditions. A The treatment with MJ04 resulted in the transition from telogen-anagen, as evidenced by the transformation of initially hairless dorsal skin to white-haired skin. Digital photographs were captured from the representative areas using a Nikon digital camera (n = 5 mice). a- Control, b-Vehicle control, cTofacitinib (0.8mg/Kg), d-Tofacitinib (0.08mg/kg). e-MJ04 (0.08mg/Kg), f- MJ04 (0.04mg/kg), g- MJ04 (0.016mg/kg), h- Baricitinib (0.1mg/kg), i- Baricitinib (0.04 mg/kg), j- Baricitinib- (0.02 mg/Kg). B Mean Weekly Body Weight: Monitoring of mean weekly body weight of athymic nude mice (NU/J Foxn1nu) mice model throughout the evaluation of MJ04's impact on hair regrowth. Here a- Control, b-Vehicle control, c-Tofacitinib (0.8mg/Kg), d-Tofacitinib (0.08mg/kg). e-MJ04 (0.08mg/Kg), f- MJ04 (0.04mg/kg), g- MJ04 (0.016mg/kg), h- Baricitinib (0.1mg/kg), i- Baricitinib (0.04 mg/kg), j- Baricitinib- (0.02 mg/Kg). The body weight of the nude mice was recorded on days 1, 7, 14, 21, and 28. C The skin samples collected from athymic nude mice (NU/J Foxn1nu) were preserved in 10% neutral buffered formalin and subsequently subjected to tissue sectioning. Skin sections (10 µm) of nude mice were stained with haematoxylin and eosin (H&E) and viewed under 10× and 40× objectives of the light microscope (Magnus, Mx21i). The histopathological examination of the samples was performed, and the hair follicles in the skin sections were graded on a scale ranging from 0 to 4 (++++). H&E stained the skin section of nude mice (×100 magnification). a and b (control & vehicle control): Normal histoarchitecture with the intact epidermis (, dermis , hypodermis , panniculus carnosus, and adventitia . c and d (Tofacitinib citrate—0.08 and 0.8 mg/kg): Mild epidermal thickening with the increased number of hair follicles [] (++++). e (MJ04—0.08 mg/kg): Minimal epidermal thickening with moderate hair follicle (++). f (MJ04—0.04 mg/kg): Mild epidermal thinning with increased hair follicles in the dermis and hypodermis (++++). g (MJ04—0.016 mg/kg): Mild epidermal thickening with increased hair follicles (+++). h (Baricitinib–0.1 mg/kg): Increased and morphologically distinct hair follicles in the dermis and hypodermis regions (+++). i and j (Baricitinib—0.04 and 0.02 mg/kg): Moderate degree of epidermal thickening with more hair follicles in the dermis and hypodermis regions (++++), and D MJ04 promotes the growth of human hair follicles under ex-vivo conditions. (a) Control group: (i) Basal length, (ii) Length posttreatment, (b) Experimental group treated with 100 μl of MJ04 (0.50 μg/μl): (i) Basal length, (ii) Length post-experiment, and (c) Experimental group treated with 100 μl of MJ04 (0.25 μg/μl): (i) Basal length, (ii) Length post-treatment. The red bracket indicates the length of the human hair follicle